Staar Surgical Co (NAS:STAA)
$ 25.12 +0.91 (+3.76%) Market Cap: 1.25 Bil Enterprise Value: 1.12 Bil PE Ratio: 0 PB Ratio: 3.55 GF Score: 83/100

Q4 2024 STAAR Surgical Co Earnings Call Transcript

Feb 11, 2025 / 10:00PM GMT
Release Date Price: $21.88 (-3.23%)

Key Points

Positve
  • Staar Surgical Co (STAA) reported strong growth in ICL sales outside of China, with a 17% increase in the fourth quarter and 13% for the full year 2024.
  • The company achieved a 22% growth in ICL sales in the Americas during the fourth quarter, outpacing the overall refractive market decline.
  • Staar Surgical Co (STAA) saw a 9% growth in ICL sales in EMEA and a 20% growth in APAC (excluding China) in the fourth quarter.
  • The company has a strong balance sheet with $230.5 million in cash equivalents and no debt, providing resilience during economic challenges.
  • Staar Surgical Co (STAA) continues to invest in commercial strategies and product pipeline, particularly in markets with potential for double-digit growth.
Negative
  • The company faced significant challenges in China, with a 13% decline in ICL sales for the full year 2024 due to weak consumer confidence and economic conditions.
  • A $27.5 million order to China was shipped but not recognized as revenue due to extended payment terms, impacting fiscal 2024 results.
  • Staar Surgical Co (STAA) anticipates minimal China ICL sales in the first half of 2025 due to elevated inventory levels.
  • The company reported a net loss of $20.2 million in fiscal 2024, compared to a net income of $21.3 million in fiscal 2023.
  • Gross margin decreased in the fourth quarter due to unrecognized revenue and costs related to manufacturing expansion and temporary facility idling.
Operator

Greetings, and welcome to the STAAR surgical fourth-quarter and fiscal 2024 earnings webcast. As a reminder, this event is being recorded today, Tuesday, February 11, 2025. (Operator Instructions)

I would now like to introduce your host, Brian Moore, Vice President of Investor Relations with STAAR Surgical.

Brian Moore
STAAR Surgical Co - Investor Relation, Vice President, Media Relations, Corporate Development

Thank you, moderator. Good afternoon, everyone, and thank you for joining us to discuss the company's financial results for the fourth-quarter and fiscal year end of December 27, 2024. Today's speakers are Tom Frinzi, Chair of the Board and CEO; and Patrick Williams, Chief Financial Officer.

The press release of our fourth-quarter and fiscal-year results was issued just after 4:00 PM Eastern Time. We have posted copies of today's earnings release and earnings presentation to the investor relations section of STAAR's website at investors.staar.com.

Before we begin, let me quickly remind you that the company comments during

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot